Rheumatic polymyalgia on the background of prostate adenocarcinoma
https://doi.org/10.30629/0023-2149-2020-98-2-153-156
Abstract
Paraneoplastic syndromes diagnosed in 7–10% of patients with malignancies in general. PNS accompany bronchogenic lung, breast, ovarian, prostate, kidney and uterus cancers most often. Neoplastic process can cause by both the acute and the chronic inflammatory response with pathologic changes of the connective tissues and vascular in various organs and systems. Diagnosis of paraneoplastic syndromes is difficult often. However, some signs should cause of rheumatologist the oncologic alertness, which were found in patients with rheumatic masks of neoplasms. Among such signs include: the occurrence of rheumatic diseases in an abnormal age; the absence of sexual dimorphism, is typical of many rheumatic diseases; the difference between the severity of clinical manifestations and the general condition of the patient with an index of inflammatory activity; the absence of separate clinical and laboratory signs typical one or another rheumatic disease; the appearance of new symptoms, not characteristic of the rheumatic diseases.
As a clinical example to illustrate the difficulty of diagnosis, this article describes a clinical case of adenocarcinoma of the prostate in 74-year-old men presenting as polymyalgia rheumatica.
About the Authors
M. A. Korolev
Research Institute of Clinical and Experimental Lymphology — branch of the Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences
Russian Federation
630060, Novosibirsk
Russian Federation
630060, Novosibirsk
E. A. Letyagina
Research Institute of Clinical and Experimental Lymphology — branch of the Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences
Russian Federation
630060, Novosibirsk
Russian Federation
630060, Novosibirsk
N. E. Banshchikova
Research Institute of Clinical and Experimental Lymphology — branch of the Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences
Russian Federation
Nadezhda Y. Banshchikova — rheumatologist, junior research associate in Laboratory of the connective tissue pathology
630060, Novosibirsk
Russian Federation
Nadezhda Y. Banshchikova — rheumatologist, junior research associate in Laboratory of the connective tissue pathology
630060, Novosibirsk
References
1. Bojinca V., Janta I. Rheumatic diseases and malignancies. Maedica (Buchar). 2012;7(4):364–71.
2. Manger B., Schett G. Paraneoplastic syndromes in rheumatology. Nat. Rev. Rheumatol. 2014;10(11):662–70.
3. Mukhin N.A., Khasabov N.N. Paraneoplastic nephropathies. Nephro logy. Guide for doctors. ed. I.E. Tareeva, Moscow, Meditsina, 2000. (in Russian)
4. Partington R.J., Muller S., Helliwell T. et al. Incidence, prevalence and treatment burden of polymyalgia rhtumatica in the UK over two decades: A population-based study. Ann. Rheum. Dis. 2018;77:1750– 56.
5. Nesher G., Breuer G.S. Giant cell arteritis and polymyalgia rheumatica: 2016 update. Rambam. Maimonides. Med. J. 2016;7(4).
6. Gonzalez-Gay M.A., Garcia-Porrua C., Salvarani C., Olivieri I., Hunder G.G. The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J. Rheumatol. 2000;27(9):2179– 84.
7. Soubrier M., Dubost J.J., Ristori J.M. Polymyalgia rheumatica: diagnosis andtreatment. Joint Bone Spine. 2006;73(6):599–605.
8. Nasonova V.A., Nasonov E.L. Revmatologiya. Natsional’noe rukovodstvo. GEOTAR-Media 2010: 622–33. (in Russian)
9. Muller S., Hider S.L. Belcher J. et al. Is cancer associated with polymyalgia rheumatica? A cohort study in the General Practice Research Database. Ann. Rheum. Dis. 2014;73(10):1769–73.
10. Leeb B.F., Bird H.A. A disease activity score for polymyalgia rheumatica. Ann. Rheu. Dis. 2004;63(10):1279–83.
11. Dasgupta B., Cimmino M.A., Maradit-Kremers H. et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann. Rheum. Dis. 2012;71:484–92.
12. Jones J.G., Hazleman B.L. Prognosis and management of polymyalgia rheumatica. Ann. Rheum. Dis.1981;40(1):1–5.
13. Alias A.I., Rodriguez E.J, Bateman H.E., Sterrett A.G., ValerianoMarcet J. Rheumatology and oncology: an updated review of rheumatic manifestations of malignancy and anti-neoplastic therapy. Bull. NYU Hospital for Joint Dis. 2012;70(2):109–14.
14. Kane I., Menon S. Carcinoma of the prostate presenting as polymyalgia rheumatica. Rheumatology. 2003;42(2):385–7.
15. Randazzo C.T., Bernard A.W., Rund D.A. Metastatic prostate cancer mimicking polymyalgia rheumatica. Case Reports Emergency Med. 2011;2011:695320.
16. Ceccato F., Una C., Regidor M., Rillo O., Babini S. Paira S. Conditions mimicking polymyalgia rheumatic. Reumatol. Clin. 2011;7(3):156--60.
17. Naschitz J.E. Rheumatic syndromes: clues to occult neoplasia. Curr. Opin. Rheumatol. 2001;13(1): 62–6.
Review
For citations:
Korolev M.A., Letyagina E.A., Banshchikova N.E. Rheumatic polymyalgia on the background of prostate adenocarcinoma. Clinical Medicine (Russian Journal). 2020;98(2):153-156. (In Russ.) https://doi.org/10.30629/0023-2149-2020-98-2-153-156
Views:
741
Email this article 